Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

combination with other approved cancer drugs. ENMD-2076 is unique-in-class because it not only inhibits Aurora A selectively, it also inhibits a cluster of kinases that are important for tumor growth, particularly growth factor receptors critical to angiogenesis. ENMD-2076 has potent antitumor activity in multiple preclinical models, including both solid tumors and hematological cancers."

James S. Burns, EntreMed President & Chief Executive Officer commented, "Further development of ENMD-2076 is consistent with both our focus on investing behind oncology drug candidates with strong single-agent activity and our continuing interest in kinase inhibitors. In keeping with our 2008 goals of cash preservation and rigorous resource management, we intend to pay the $2 million Phase 1 milestone to Miikana shareholders in shares of EntreMed common stock. Our goals for this program over the next twelve months are to complete the clinical trial in solid tumor patients, initiate a clinical trial in patients with hematological cancers, and secure a pharmaceutical partner to help accelerate the development of ENMD-2076."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at '/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... in accordance with Securities and Exchange Commission rule 10b5-1. ... Corporation, is a minority owner of this entity that ... Herbert does not have control of this entity, but ... for a portion of the shares owned by that ...
(Date:3/27/2015)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , today reported financial ... 31, 2014.  The Company reported a ... for the three months ended December 31, 2014.  This ...
(Date:3/26/2015)... Louisville, CO (PRWEB) March 26, 2015 ... agency has formed a strategic alliance with Designing Gig ... to their clients. , “Forging this alliance ... company. Now we can extend a comprehensive, end-to-end, ... design, development, strategy, and execution,” said Chuck Miller, president ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced mechanical ... transit-time flow measurement solutions, are collaborating on a miniature ... the HeartAssist5® Left Ventricular Assist Device (LVAD). ... and peace of mind. , The Transonic flow ... 1/6th of the power required by earlier flow board ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... Recent events in Japan have caused the world to ... be a cause for concern – especially if radiation ... proliferating cells of the body. Cells of the hematopoietic ... two such cell types. Damage to these cells initiates ...
... Inc. (Nasdaq: TNGN ), a leader in regenerative ... live audio webcast on Friday, March 25, 2011 at 8:30 ... fourth quarter 2010 financial results.   To participate ... and reference access code 55045101. This conference ...
... 2011 Veran Medical Technologies announced today that it has ... in the financing included existing investors and a new strategic ... commercialize products on the IG4 four-dimensional image guidance platform of ... as it will enable us to rapidly commercialize the products ...
Cached Biology Technology:Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 3Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011 2
(Date:3/11/2015)... --  The Sync Project™ today announced the ... harness music to improve health. The platform maps ... of physiology, enabling the study of the therapeutic ... It is designed for medical and health research, ... and accelerate the discovery of the clinical applications ...
(Date:3/5/2015)... SAO PAULO , March 5, 2015 In ... with 41 percent of companies already using these solutions and ... of 2015. Of the latter, approximately 25 percent of the ... time. While the majority of companies in the ... is anticipated that the hybrid model will command significant attention ...
(Date:3/2/2015)... 2015   Neurotechnology , a provider of high-precision ... SentiGaze Software Development Kit (SDK). The SentiGaze algorithm ... off-the-shelf webcams to track eye movements and generate heatmaps ... Heatmaps can be used for applications such as analysis ... The SDK can also be used to develop interfaces ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... Scientists have determined that Helicobacter pylori, the bacterium that ... requires the vitamin B6 to establish and maintain chronic ... online journal mBio . This finding, along ... to utilize the vitamin, could lead to the development ...
... in academia bemoan the fact that their lifestyles do ... they would like. Surprisingly, male scientists harbor more regrets ... University sociologist Elaine Howard Ecklund. Ecklund and co-author ... of career, life outside work and the intersection of ...
... Georgia Institute of Technology has received a $10 million ... (NSF) to develop novel computing techniques for measuring and ... will be used to enable new approaches for identifying ... In addition, these methods may potentially improve the delivery ...
Cached Biology News:Rice sociologist finds male scientists regret parenthood decisions more than female counterparts 2Rice sociologist finds male scientists regret parenthood decisions more than female counterparts 3NSF awards $10M to develop computing techniques for measuring and analyzing child behavior 2NSF awards $10M to develop computing techniques for measuring and analyzing child behavior 3
Rabbit Serum New Zealand or California Origin...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
Human ICAT Affinity Purified Polyclonal Ab...
... [APS 26] to Presenilin 2 Alzheimer's ... of the disease carry mutations in the ... precursor protein (APP). These disease-linked mutations result ... of amyloid-beta (main component of amyloid deposits ...
Biology Products: